Spread | 0.07 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 14.24 |
Open | 14.08 |
1-Year Change | -19.95% |
Day's Range | 13.88 - 14.29 |
Tactile Systems Technology, Inc. is a medical technology company focused on developing medical devices for the treatment of chronic diseases. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. It is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. It possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
BRIEF: For the fiscal year ended 31 December 2021, Tactile Systems Technology Inc revenues increased 11% to $208.1M. Net loss increased from $620K to $11.8M. Revenues reflect Flexitouch system segment increase of 8% to $176.2M, Entre/Actitouch systems segment increase of 15% to $26.7M. Higher net loss reflects Sales and marketing - Balancing value increase of 11% to $82.7M (expense), Stock-based Compensation in SGA increase of 13% to $5.4M (expense).